Trending...
- California: Governor Newsom responds to DOGE's dismantling of AmeriCorps: 'Middle finger to volunteers. We will sue'
- California: Governor Newsom proclaims Arab American Heritage Month
- 100 days after the fires: California and Los Angeles rebuild, recover, and rise together
HOPE Therapeutic Subsidiary Focused on Developing a Best-in-Class Network of Clinics for Patients with Suicidal Depression and Related Disorders. HOPE is Planned to be Spun Out as a Separate Company to be Owned by NRXP Shareholders, and New Investors. Effort to be Funded Apart from NRXP.
WILMINGTON, Del. - Californer -- For more information on $NRXP visit: https://www.nrxpharma.com/ OR https://compasslivemedia.com/case-study/nrx-pharmaceuticals/
NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain.
NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
More on The Californer
NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
HIGHLIGHTS
Developing Therapeutics for the Treatment of CNS Disorders, Specifically Suicidal Bipolar Depression, Chronic Pain and PTSD.
Company Funded For New Drug Applications (NDAs) for NRX-100 (ketamine) and NRX-101
Audit of HOPE Therapeutics Subsidiary Complete, SEC Filing of Spinout Planned for Current Quarter.
Secured $10.8 - $16.3 Million Convertible-Debt Funding from an Institutional Investor.
NRX-100 NDA for Suicidal Depression Based on Data from Four Clinical Trials in Nearly 1000 Participants Demonstrating Highly Significant Efficacy.
Ketamine Findings Confirmed in Published 43,000 Person Cohort Study.
More on The Californer
Phase 2b/3 Trial Data Presented at the American Society of Clinical Psychopharmacology. Profile Demonstrates Possible Best in Class.
Plans to file New Drug Application for Accelerated Approval under Breakthrough Therapy Designation and Priority Review of NRX-101.
Stability Data Continues to Mature on Three Manufacturing Lots Required for the NRX-100 (IV ketamine) NDA filing.
Company Announced Alignment with FDA on its Pediatric Study Plan for NRX-100, Also a Requirement for Filing of NDA.
Media Contact
Company Name: NRx Pharmaceuticals, Inc.
Contact Person: Matthew Duffy, Chief Business Officer
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Country: United States
Website: https://www.nrxpharma.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
NRx Pharmaceuticals, Inc. (Stock Symbol: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain and PTSD. NRXP is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain.
NRXP has partnered with Alvogen Pharmaceuticals around the development and marketing of NRX-101 for the treatment of suicidal bipolar depression. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
More on The Californer
- Greek Government Issues Landmark Ministerial Order Addressing Citizenship of Greek-born adoptees
- Stout Surpasses 60,000 Acres and 3 Billion Plants Scanned
- OpsVeda Announces Launch of TariffSight, the World's First Comprehensive Platform to Address Tariff-Driven Challenges
- UC Ventures Appoints Julie Chang as Managing Director of Investments
- MAJOR New release of Krypto500 (ELF-HF) Sigint - COMINT software
NRXP is working on a New Drug Application for NRX-100 (IV ketamine) in the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRXP was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
HIGHLIGHTS
Developing Therapeutics for the Treatment of CNS Disorders, Specifically Suicidal Bipolar Depression, Chronic Pain and PTSD.
Company Funded For New Drug Applications (NDAs) for NRX-100 (ketamine) and NRX-101
Audit of HOPE Therapeutics Subsidiary Complete, SEC Filing of Spinout Planned for Current Quarter.
Secured $10.8 - $16.3 Million Convertible-Debt Funding from an Institutional Investor.
NRX-100 NDA for Suicidal Depression Based on Data from Four Clinical Trials in Nearly 1000 Participants Demonstrating Highly Significant Efficacy.
Ketamine Findings Confirmed in Published 43,000 Person Cohort Study.
More on The Californer
- New Build-to-Suit VA Medical Office Facility Coming to Highland Heights, KY
- Armed With Purpose and Trained To Lead
- Introducing the Heart-Shaped Pearl Earrings — A Romantic New Addition from Sairahaz Jewelers
- Personalized Name Necklaces Under $200 — The Perfect Gift for Any Occasion
- City of Long Beach to Host and Fund 2025 Pride Parade, Announces Grand Marshals
Phase 2b/3 Trial Data Presented at the American Society of Clinical Psychopharmacology. Profile Demonstrates Possible Best in Class.
Plans to file New Drug Application for Accelerated Approval under Breakthrough Therapy Designation and Priority Review of NRX-101.
Stability Data Continues to Mature on Three Manufacturing Lots Required for the NRX-100 (IV ketamine) NDA filing.
Company Announced Alignment with FDA on its Pediatric Study Plan for NRX-100, Also a Requirement for Filing of NDA.
Media Contact
Company Name: NRx Pharmaceuticals, Inc.
Contact Person: Matthew Duffy, Chief Business Officer
Email: mduffy@nrxpharma.com
Phone: (484) 254-6134
Country: United States
Website: https://www.nrxpharma.com
DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website
Source: Corporate Ads
0 Comments
Latest on The Californer
- Dreame Technology Expands US Footprint with New San Diego Location
- Pelican Reef Group Announces Grand Opening of New High Point Showroom – IHFC Building H-621 & Event April 27th, 2025
- PATH Honors Sayed Ali of Interpreters Unlimited For His Dedication to Fighting Homelessness
- FIELD MEDICAL ANNOUNCES FIRST-IN-HUMAN DATA FOR FOCAL PFA IN SCAR-RELATED VT AT HEART RHYTHM 2025 USA - English APAC - English USA - English
- NaturismRE Launches the 11 Levels of Naturism: A Groundbreaking Framework Guiding the Global Naturist Journey
- K2 Integrity and Sonata One Partner to Accelerate Capital Raising, Reduce Risk, and Deliver Scalable Advisory Services for Private Fund Managers
- Startup Agency Launches Fractional Consulting for Founders
- The World's No.1 Superstar™ Walks Where Legends Rest: A Sacred Encounter in Rome Before the Pope's Passing
- Lafayette's Leila Douglah Wins 3rd Place in Sub-Zero, Wolf, and Cove Global Kitchen Design Contest
- Kitchen Exhaust Hood Cleaning in Orange County
- California: Governor Newsom announces appointments 4.22.25
- Coming Up on "Financial Freedom with Tom Hegna" Financial Expert Parker Faulkner
- California: PHOTOS: Governor Newsom, First Partner Siebel Newsom celebrate Earth Day with next generation of agricultural stewards
- Tobu Railway Announces a Price Revision on the "NIKKO PASS All Area" and "NIKKO PASS World Heritage Area," from April 20, 2025
- Flexi-View Lending Closes $20 Million Business Loan for Strategic Purchase in Frankfort, KY
- Kemeny, Ramp & Renaud, LLC Welcomes Prominent Trusts and Estates Attorney Gary B. Cornick to Its Firm
- DESERT BLOOM™ Makes a Bold Entrance, Kicking Fast Fashion Off Its High Horse with Earth Day Launch
- The Bancorp, Inc. (TBBK) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
- SF-Based Agency Launches First-Ever Fractional Recruiter Model
- California: Governor Newsom welcomes students, teachers and parents back as Palisades Charter High School is set to resume in person instruction